Dfn-15
Hurler Syndrome
Masonic Cancer Center, University of MinnesotaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Hurler Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aldurazyme Genzyme, a Sanofi Company | Phase 4 | A |
IDURONIDASE, .ALPHA.-L-(8-HISTIDINE) (HUMAN) Masonic Cancer Center, University of Minnesota | Phase 4 | BB |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2 | BB |
Thiotepa University of Florida | Phase 2 | BB |
CYCLOSPORIN A Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 19 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →